MS HB314

Authorizes the Mississippi State Department of Health to select a consortium (consisting of a drug developer, institution of higher learning, and hospital) to conduct FDA clinical trials for ibogaine as a treatment for opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions

Requires the selected consortium to submit an Investigational New Drug (IND) application to the FDA, seek breakthrough therapy designation, and coordinate with ibogaine trials being conducted in other states

Mandates that state funding disbursements require dollar-for-dollar matching funds from non-state sources, with clinical trials limited to institutions of higher learning or hospitals as trial sites

Allocates at least 20% of all revenue from intellectual property and commercial rights arising from the trial to the State General Fund, with the remainder distributed among consortium members

Requires that if ibogaine receives FDA approval, a licensed physician must supervise administration at a hospital or licensed health care facility to ensure patient safety